JANICE CUNNINGHAM: Open Payments
NPI 1700151651 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,134 in 79 payments from 12 companies in 2025. Trend: 2023 $1,233 · 2024 $1,203 · 2025 $1,134
Food & beverage: $1,134
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $302 |
| ABBVIE INC. | 14 | $171 |
| Janssen Pharmaceuticals, Inc | 12 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $112 |
| Neurocrine BioSciences, Inc. | 6 | $93 |
| Alkermes, Inc. | 4 | $80 |
| Axsome Therapeutics, Inc. | 4 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
| Gilead Sciences, Inc. | 1 | $22 |
Products named: REXULTI, VRAYLAR, ABILIFY MAINTENA, CAPLYTA, INGREZZA, INVEGA SUSTENNA, ARISTADA, Auvelity.
Industry payments across NE — which companies pay providers there.
